1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Peptron, Inc.

Peptron, Inc.

KKRX:087010
104,500.00
KRW
+2,200.00
(+2.15%)
-714.65EPS
6.82TMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
334.56
247.06
263.29
205.87
239.25
111.63
203.04
321.05
281.77
162.46
151.79
242.53
257.44
Basic EPS, GAAP
-410.37
-239.86
-268.36
-283.44
-230.83
-1,098.12
-1,196
-729
-730
-774
-1,061
-595
-715.22
Free Cash Flow per Basic Share
-483.43
-236.38
-480.58
-1,760.76
-889.88
-911.48
-1,087.96
-551.99
-651.13
-630.47
-718.95
-1,015.04
-1,295.49
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
723.45
1,369.03
3,998.45
3,128.28
2,795.19
1,740.77
3,739.46
3,019.5
2,574.77
1,757.76
6,532.58
6,109.64
5,850
Tangible Book Value per Share
577.97
1,270.88
3,904.22
3,060.48
2,736.05
1,684.88
3,708.07
2,990.16
2,542.04
1,669.47
6,410.4
5,972.9
5,715.11
Basic Weighted Avg Shares
7
11
12
16
16
16
15
21
21
21
21
23
23
Sales/Revenue/Turnover
2,484
2,812
3,131
3,215
3,862
1,801
3,121
6,625
5,814
3,342
3,152
5,635
5,981
Operating Margin (%)
-105.06
-101.34
-113.85
-148.47
-204.72
-705.32
-564.17
-236.37
-261.9
-475.3
-524.33
-377.25
-379.24
Depreciation Expense
578
598
602
594
900
2,651
3,266
3,510
5,054
2,894
2,691
2,715
2,863
Net Income, GAAP
-3,046
-2,730
-3,191
-4,427
-3,726
-17,718
-18,382
-15,042
-15,063
-15,922
-22,034
-13,824
-16,617
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-122.66
-97.09
-101.93
-137.68
-96.48
-983.7
-589.03
-227.07
-259.08
-476.43
-699
-245.33
-277.82
Working Capital
4,699
11,931
48,182
22,356
28,826
17,732
43,528
26,069
12,511
1,080
121,382
108,313
85,873
LT Debt
2,200
- -
2,000
2,000
21,881
29,145
9,140
6,101
82
4,526
8,144
25,785
26,348
Total Equity
7,181
17,228
53,209
48,945
45,098
28,086
77,133
62,283
53,109
36,127
151,709
142,009
135,974
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-23.35
-9.18
-8.72
-7.93
-48.42
-34.94
-21.58
-26.11
-35.68
-23.46
-9.41
-11.69

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
3,776
3,770
3,754
LT Borrowings
26,578
25,593
26,187
LT Finance Leases
232
192
161
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
6,973,017
5,903,821
6,821,935

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
115,699
115,324
93,549
Cash, Cash Equivalents & STI
107,030
106,918
83,643
Accounts Receivable, Net
341
612
934
Inventories
240
1,770
2,245
Total Current Liabilities
7,294
7,012
7,676
Payables & Accruals
- -
- -
- -
ST Debt
3,776
3,770
3,754
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
57.75%
49.52%
-6.39%
Free Cash Flow
51.76%
11.13%
57.95%
Net Income, GAAP
40.78%
-2.24%
-37.26%
Sales/Revenue/Turnover
18.46%
26.12%
78.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
477
542
588
1,545
3,152
2025
1,620
1,426
1,602
987
5,635
2026
1,967
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-196
-398
-232
-234.7
-1,061
2025
-143
-163.53
-87.16
-201.35
-595
2026
-263.08
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ho-Il Choi
Full Time Employees
163
Sector
Health technology
Industry
Biotechnology
Address
37-24, Yuseong-daero 1628 beon-gil Daejeon DE South Korea 340-54
IPO Date
Jul 22, 2015
Website
peptron.co.kr
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Peptron Inc (087010.KQ) is a South Korea-based biotechnology company focused on the development, manufacture, and distribution of peptide-based sustained-release medications for chronic diseases. Founded in 1997 and headquartered in Daejeon, South Korea, the company operates primarily in the biopharmaceutical sector, targeting markets in prostate cancer, acromegaly, type 2 diabetes, neurodegenerative disorders including Parkinson's and Alzheimer's, endometriosis, uterine fibroids, puberty disorders, and obesity; its core offerings include proprietary sustained-release formulations such as Luphere Depot (leuprolide acetate for prostate cancer, endometriosis, uterine fibroids, and central precocious puberty), SR-Octreotide (PT201 for acromegaly and hyperpituitarism), SR-Exenatide (PT302 for type 2 diabetes and PT320 for Parkinson's disease and other neurodegenerative conditions), PAb 001 (anticancer therapy), Dernak filler (bioequivalence product), peptide synthesis services for research institutions and pharmaceuticals, and peptide raw materials; Peptron leverages key technologies including Long Acting sustained-release systems and SmartDepot, an ultrasonic spray drying platform for microsphere injectables, with products distributed domestically and exported to over 30 countries. In recent developments, Peptron closed a KRW 24.2 billion private placement of zero-coupon convertible bonds in August 2025 with investors including LS Securities, NH Investment & Securities, Samsung Securities, and various technology funds to support pipeline advancement; the company entered a strategic partnership with Eli Lilly in October 2024 to apply SmartDepot technology to Lilly's peptide drugs, enhancing its collaborative drug discovery efforts.